← BackNutex Health Inc. · Business Services, NECNUTX
Elevated riskNext report: Due any day
The short versionA profitable company with shrinking sales. Institutions are adding.
Going well
- Profitable
- Sales up 82% last year
- Brings in more cash than it spends
Watch out for
- Sales down 14% in the latest quarter vs a year ago
- Share count growing 16.9% a year (dilution)
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 5.7% to their holdings in the quarter ending June 2026 (99 bought, 46 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$208.36-0.5% that day
- Company value
- $1.4B
- Share price times all shares
- Price vs profit (P/E)
- 8.2x
- You pay about $8 for each $1 of yearly profit
- Price vs sales
- 1.7x
- Company value is 1.7 times a year of sales
- Cash vs value
- 14%
- Cash as a share of company value
- Debt vs value
- 3%
- Debt as a share of company value
From NUTX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$210.8M-14% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $846.7M, up 6.9% from the 12 months before. Over 5 years, sales grew about 26% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.30.7%
- PassDebt under half of equityNot relying on borrowed money.0.13x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.8.1%
- MissProfitable every yearSteady profits, not one good year.5 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$245.6M
- MissShare count not growingNot diluting owners. Falling means buybacks.+59.6% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.50.8%
- Revenue
- $875.3M
- +82.4% vs prior year
- 5-year growth
- +26.1%/yr
- revenue, per year
- Total debt
- $42.5M
- 0.13x equity
- Current ratio
- 3.41x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $210.8M
- -13.6% YoY
- EPS
- $9.38
- vs -$2.95
- Op. margin
- 57.8%
- +44.0 pts
- Gross margin
- 67.0%
- +15.8 pts
- Free cash flow
- $31.7M
- Share count
- +17.1%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 1.0
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+5.7%Institutions added 5.7% to their holdings. 99 bought, 46 sold. 7 quarters of net buying in a row.
Shares held by institutions2.9M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+15.8%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.1x · $39.6M debtShares outstandingLatest reported
7MWhy elevated risk- Share count growing 15.8% a year (dilution)
- Late quarterly report notice
Next reportDue any dayEstimated from the same quarter last year
- Results filedAug 6
- Results filedApr 30
- Results filedMar 5
- Results filedNov 19, 2025
- Results filedNov 18, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.